期刊文献+

SHP2不同突变体对乳腺癌细胞迁移和侵袭能力的影响

Effect of different SHP2 mutants on migration and invasion of breast cancer cell
下载PDF
导出
摘要 目的:采用慢病毒感染的方式将SHP2基因和SHP2突变体导入乳腺癌细胞系MDA-MB-231中,研究SHP2及其各突变体对乳腺癌细胞迁移和侵袭能力的影响。方法:构建SHP2-WT和SHP2-T468M、SHP2-N308D和SHP2-2YF 3个突变体的慢病毒载体,完成慢病毒包装后,感染乳腺癌细胞系MDA-MB-231稳定表达。通过蛋白免疫印记检测高表达情况,免疫荧光观察定位情况,划痕、Transwell实验检测细胞的迁移和侵袭能力。结果:SHP2-WT增强了乳腺癌细胞迁移和侵袭能力,SHP2-T468M,SHP2-N308D与对照相比无显著影响,SHP2-2YF与对照相比降低了乳腺癌细胞的迁移和侵袭能力。结论:SHP2-WT能显著增强乳腺癌细胞迁移和侵袭能力,这可能与其磷酸酶活性无关,而与其542位和580位酪氨酸的磷酸化有关。 Objective:To explore the effects of SHP2 and its mutants on migration and invasion of breast cancer cells by transfecting SHP2 and SHP2 mutants into breast cancer cell line MDA-MB-231. Methods: First inglentiviral vector SHP2-WT and three mutants of SHP2-T468 M, SHP2-N308 D and SHP2-2YF were constructed, and then the lentiviral packaging was completed to infect breast cancer cell line MDA-MB-231 for stable expression. The expression, location, cell migration and invasion were detected by western blotting,immunofluorescence, wound-healing and transwell assay respectively. Results: Migration and invasion abilities of breast cancer cell were enhanced by SHP2-WT. SHP2-T468 M, SHP2-N308 D had no significant effect compared with the control group. The SHP2-2YF lessened the migration and invasion in breast cancer cells. Conclusion: SHP2-WT can significantly increase the invasion and migration of breast cancer cells, which may not be related to the phosphatase activity, but associate with 542 and 580 tyrosine phosphorylation.
出处 《天津医科大学学报》 2015年第2期93-96,共4页 Journal of Tianjin Medical University
基金 国家自然科学基金资助项目(81372844) 教育部博士点基金资助项目(20131202110002) 天津医科大学科研基金资助项目(2009ky21)
关键词 乳腺癌 SHP2 磷酸酶活性 迁移 侵袭 breast cancer SHP2 phosphatase activity migration invasion
  • 相关文献

参考文献11

  • 1Jemal A, Bray F, Center M M, et al. Global cancer statistics[J]. CA Cancer J Clin, 2011,61 (2):69.
  • 2Aceto N. Sausgruber N, Brinkhaus H, et al. Tyrosine phosphatase SHP2 promotes breast cancer progression and maintains tumor-ini- tiating cells via activation of key transcription factors and a positive feedback signaling loop[J]. Nat Med, 2012,18(4):529.
  • 3Chan G, Kalaitzidis D, Neel B G. The tyrosine phosphatase Shp2 (PTPN 11) in eancer[J ]. Cancer Metaslasis Rev, 2008,27(2): 179.
  • 4Dance M, Montagner A, Salles J P, el al. The molecular functions of Shp2 in the Ras/Mitogen-activattxt protein kinase (ERKI/2) pathway [ J]. Cell Signal, 2008,20(3):453.
  • 5Grossmann K S, Ros6rio M, Birchmeier C, et al. The tyrosine phos- phatase Shp2 in development and cancer[J]. Ad,: Cancer Res, 2010, 106:53.
  • 6Hartman Z R, Schaller M D, Agazie Y M. The tyrosine phosphatase SHP2 regulates focal adhesion ki nase to promote EGF-induced lamellipodia persistence and cell migralion [J]. Mol Cancer Res. 2013,11(6):651.
  • 7Tidyman W E, Rauen K A. The RAS opathies: developmental syn- dromes of Ras/MAPK pathway dysregulation [J ]. Curr Opin Gnet Dev, 2009,19(3):230.
  • 8Tartaglia M, Gelb B D.Disorders of dysregulated signal traffic through the RAS-MAPK pathway: phenotypic spectrum and molec- ular mechanisms[J]. Ann N Y Acad Sci, 2010.1214:99.
  • 9Araki T, Nawa H, Neel B G. T yrosyl phosphou, lation of Shp2 is re- quired for normal ERK activation in response to some, but not all, growth factors[J]. J Biol Chem, 2003,278(43):41677.
  • 10Cleghon V, Feldmann P. Ghiglione C, et al. Opposing actions of CSW and RasGAP modulate the strength of Torso RTK signaling in the Drosophila terminal pathway[ J]. Mol Cell, 1998,2(6):719.

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部